Skip Nav Destination
Issues
1 July 2025
-
Cover Image
Cover Image
The cover shows double immunofluorescence of phosphorylated ERK and CK19 of pancreatic cancer from KPC model. Engagement of KRAS inhibitor to its target was detected by MRI markers and confirmed by reduction of p-ERK immunofluorescence. For details, see the article by Gupta and colleagues on page 2663 of this issue. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1078-0432
EISSN 1557-3265
Issue Sections
CCR Translations
CCR Perspectives in Regulatory Science and Policy
Reviews
Perspectives
Clinical Trials: Targeted Therapy
Application of Neoadjuvant Docetaxel plus Cisplatin in Early-Stage Triple-Negative Breast Cancer (HELEN-001): Results from a Phase II Trial
Dechuang Jiao; Jianghua Qiao; Xianfu Sun; Chengzheng Wang; Zhenduo Lu; Chongjian Zhang; Lianfang Li; Min Yan; Yueqing Feng; Yong Zhou; Miao Deng; Xinlan Liu; Mingde Ma; Haiquan Jia; Qingxin Xia; Geok Hoon Lim; Naohiro Ishii; Armando Orlandi; Fernando Hernanz; Xiuchun Chen; Zhenzhen Liu
Ribociclib in Sequential Combination with Doxorubicin in Anthracycline-Naïve Advanced Soft-Tissue Sarcomas: Results of a Dose-Finding Phase Ib Study
Lara E. Davis; Limin Zhu; Emile Latour; Nathan McMahon; Go Nishikawa; Florence Choo; Kevin D. Nusser; Janét Pittsenbarger; Reid Burch; Byung Park; Gordon B. Mills; Jessica L. Davis; Monika Davare; Christopher W. Ryan
Venetoclax plus Modified-Intensity Idarubicin and Cytarabine Treatment as First-Line Treatment for Newly Diagnosed Pediatric Acute Myeloid Leukemia
Shiyuan Wang; Mingyan Jiang; Yaqin Wang; Lixian Chang; Beibei Zhao; Xiaoming Liu; Benquan Qi; Shuchun Wang; Tianfeng Liu; Xiaoyan Zhang; Yumei Chen; Fang Liu; Ye Guo; Xiaojuan Chen; Li Zhang; Yao Zou; Wenyu Yang; Ju Gao; Xiaofan Zhu; Min Ruan
Clinical Trials: Immunotherapy
INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Jérôme Fayette; Lisa Licitra; Kevin Harrington; Robert Haddad; Lillian L. Siu; Yi-Chun Liu; Makoto Tahara; Jean-Pascal Machiels; Danny Rischin; Tanguy Y. Seiwert; Robert L. Ferris; Ulrich Keilholz; Amanda Psyrri; Bhumsuk Keam; Paolo Bossi; Robert Metcalf; Ching-Yun Hsieh; Paul M.J. Clement; Pavel Isaev; Ali Mudunov; José Dinis; Ann Hoeben; Stefan Kasper; Konrad Klinghammer; Michael Hwang; Jorge Blando; Olivier Serrano; Dario Ruscica; Roger B. Cohen; for the INTERLINK-1 investigators
Effective TIL Therapy for Patients with Checkpoint-Resistant Melanoma without Lymphodepleting Regimens Requires IFNα
Els M.E. Verdegaal; Anique L.C. Verpoorte; Monique K. van der Kooij; Linda de Bruin; Marten Visser; Caroline E. van der Minne; Vera Weeda; Inge C.F.M. Roozen; Mare A. Jonker; Inge M. Westra; Pauline Meij; Frank M. Speetjens; Stephanie M. Zunder; Gerrit-Jan Liefers; Saskia J. Santegoets; Sjoerd H. van der Burg; Ellen H.W. Kapiteijn
Ad-SGE-DKK3 Gene Therapy Overcomes Resistance to Immune Checkpoint Blockade in Pleural Mesothelioma
Hee-Jin Jang; Meera Patel; Daniel Y. Wang; Sung Wook Kang; Jong Min Choi; Claire Lee; Monica Vilchis; Ji Seon Shim; Sonali Mitra; Priyanka Ranchod; Allen Kuncheria; William Hudson; Peter Jindra; Veronica Lenge De Rosen; Maheshwari Ramineni; Ernest Ramsay Camp; Farrah Kheradmand; R. Taylor Ripley; Shawn S. Groth; Hyun-Sung Lee; Bryan M. Burt
A Phase II Randomized Study of Paclitaxel Alone or Combined with Pelareorep with or without Avelumab in Metastatic Hormone Receptor–Positive Breast Cancer: The BRACELET-01/PrE0113 Study
Amy S. Clark; Fengmin Zhao; Paula Klein; Alberto J. Montero; Carla Falkson; Elisa Krill-Jackson; Kendrith Rowland; Sagar Sardesai; Jason Incorvati; Patrick Dillon; Antonio C. Wolff; Richard Trauger; Thomas C. Heineman; Matthew C. Coffey; Kathy D. Miller
Research Briefs: Precision Medicine and Therapeutics
Precision Medicine and Imaging
Characterization of Plasma Cell-Free DNA Variants as of Tumor or Clonal Hematopoiesis Origin in 16,812 Advanced Cancer Patients
Daniel Magee; Valeriy Domenyuk; Jim Abraham; Nieves Perdigones Borderias; Jeff Swensen; Praveena Solipuram; Adanma Ayanambakkam; Raja Mehdi; Jagathi Challagalla; Elisabeth Heath; Megan Landsverk; Magdalena Jurkiewicz; Brian Shimkus; Ian Pinto; Daniel Patterson; David Hsiehchen; Supriya Koya; Bradley Somer; Michel Velez; Anthony F. Shields; Jennifer Cultrera; Jennifer R. Ribeiro; Robert Hahn-Lowry; George W. Sledge; Matthew Oberley; Milan Radovich; David Spetzler
Translational Cancer Mechanisms and Therapy
p-AKT Protein Expression Predicts Response to AKT Inhibitor Combined with Docetaxel Therapy in Adenocarcinoma and Neuroendocrine Prostate Cancer
Hipacia Werneck Gomes; Natalie L. Lister; Shivakumar Keerthikumar; Birunthi Niranjan; Michelle G. Richards; Andrew Ryan; Edmond M. Kwan; Gail P. Risbridger; Renea A. Taylor
Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B-cell Lymphoma
Khushali Jhaveri; Ram Thapa; Dalia Ercan; Aditi Saha; Jerald Noble; Pranit Singh; Johannes Fahrmann; Neeraj Saini; Ranran Wu; Jennifer B. Dennison; Sam Hanash; Robert R. Jenq; Karnav Modi; Nicholas Figura; Julio Chavez; Bijal Shah; Taiga Nishihori; Aleksandr Lazaryan; Farhad Khimani; Christina Bachmeier; Kenneth Gage; Asmita Mishra; Fabiana Perna; Marco L. Davila; Jay Spiegel; Kai Rejeski; Marion Subklewe; Frederick L. Locke; Ciara Freeman; Nathan Parker; Michael D. Jain
Quantitative Protein Expression of Antibody–Drug Conjugate Targets in EGFR Mutated and Wild-type Non–Small Cell Lung Cancer
Ioannis P. Trontzas; Mengni He; Anna Wurtz; Charles J. Robbins; Nathaniel Robinson; Katherine Bates; Matthew Liu; Thazin N. Aung; Liam Scott; Nay Chan; Sneha Burela; Jacob Schillo; Daniel C. Liebler; Salisha Hill; Ryan D. Morrison; Ioannis Vathiotis; Konstantinos N. Syrigos; Sarah B. Goldberg; Katerina Politi; David L. Rimm
Presurgical Ablative Radiation Is Associated with Local Control and Immune Response in Pancreatic Cancer
Peter Q. Leung; Eslam A. Elghonaimy; Ahmed M. Elamir; Megan Wachsmann; Song Zhang; Neha Barrows; Hollis Notgrass; Ethan Johnson; Cheryl M. Lewis; Rachel von Ebers; Cassandra Hamilton; Samy Castillo-Flores; Ricardo E. Nunez-Rocha; Grace Josephson; Zhikai Chi; Salwan Al Mutar; Patricio M. Polanco; Nina N. Sanford; Syed M. Ali Kazmi; Matthew R. Porembka; David Hsiehchen; Adam C. Yopp; John C. Mansour; Muhammad S. Beg; Herbert J. Zeh, III; Todd A. Aguilera
Antitumor Immunity Mediated by Engineered Stem Cells Exploiting TRAIL-Induced Cell Death and FLT3L Immunomodulation
Thijs A. van Schaik; Kok-Siong Chen; Nobuhiko Kanaya; Lucia Moreno-Lama; Nicolas W. Freeman; Mian Wang; Wanlu Li; Yu Shrike Zhang; Vladimir Vrbanac; Raymond Huang; Hiroaki Wakimoto; David Reardon; Khalid Shah
Low Allele Frequency Variants Identified on Germline Multi-Gene Panel Testing for Cancer Predisposition Can Suggest the Presence of Constitutional Mosaicism
Adela Rodriguez-Hernandez; Linda M. Polfus; Brittany L. Bychkovsky; Beth Souders; Aleix Prat; Barbara Adamo; Judy E. Garber; Carolyn Horton; Huma Q. Rana
Clinical Context Shapes the Relationship between Genomic Alterations and Response to AR Inhibitors and Chemotherapy in Metastatic Prostate Cancer
Kalpit Shah; Matthew H. Secrest; Wei Zhou; Shu Wang; Dan Canter; Yuxiang Zhang; Dexter Jin; Ethan Sokol; Malgorzata Nowicka; Armande Ang Houle; Ciara Metcalfe; Steven Gendreau; Carsten Schröder; Matthew Wongchenko; Gerhardt Attard
Corrections
Correction: AT13148 Is a Novel, Oral Multi-AGC Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity
Timothy A. Yap; Mike I. Walton; Kyla M. Grimshaw; Robert H. te Poele; Paul D. Eve; Melanie R. Valenti; Alexis K. de Haven Brandon; Vanessa Martins; Anna Zetterlund; Simon P. Heaton; Kathrin Heinzmann; Paul S. Jones; Ruth E. Feltell; Matthias Reule; Steven J. Woodhead; Thomas G. Davies; John F. Lyons; Florence I. Raynaud; Suzanne A. Eccles; Paul Workman; Neil T. Thompson; Michelle D. Garrett
Advertisement
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds